Anti-Infective Agents - Global Market Outlook (2017-2023)

According to Stratistics MRC,the Global Anti-Infective Agents Market is accounted for $86.7 billion in 2016 and expected to grow at a CAGR of 3.8% to reach $113.16 billion by 2023. Rising incidences of infectious diseases such as HIV, H1N1, and Ebola virus, awareness amongst the patients, commercialization of pipeline products, Govt collaborating with pharmaceutical companies for the development of new agents, development of new multi-drug resistance against micro-organisms are boosting the market growth. Treatment rates for communicable diseases in developing countries and treatment of Community Acquired Bacterial Pneumonia (CABP) are expected to impart the market growth. Growing resistance of infection to the drug therapies, high price of drugs, competition between generic manufacturers and perilous reimbursement policies will impede market growth.

Based on Product, most of the Antibacterial agents are in pipeline for the modifications of existing antibiotic classes. More innovative products are required against pathogens with no cross- or co-resistance to existing classes. Many of the products in the clinical pipeline are already funded by research grants from public and philanthropic institutions.For instance, Delafloxacin was approved by the US Food and Drug Administration on 21 June 2017.

North America commanded the anti-infective agents market and is followed by Europe. Asia Pacific is the fastest growing market due to improvements in healthcare infrastructure, demand for drugs and ongoing government initiatives for various control programs.

Some of the key players in Global Anti-Infective Agents market are Pfizer Ltd, Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd., AstraZeneca Plc, Boehringer Ingelheim, Bristol-Myers Squibb Co, Abbott Laboratories, Bayer Healthcare AG, Cipla Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Merck & Co., Inc, Novartis AG, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Panacea Biotech Ltd and Claris Life Sciences Ltd.

Products Covered:

• Antifungal agents
  • Azoles
  • Polyenes
  • Allylamines
  • Macrolides derivatives
  • Cresemba
  • Echinocandins
• Antiviral agents
  • Non-structural protein 5A (NS5A) inhibitors
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • Protease Inhibitors
  • Transcriptase Inhibitors
  • Neuraminidase inhibitors
  • Integrase strand transfer inhibitor
  • Chemokine receptor antagonist
  • DNA Polymerase Inhibitors
  • Nucleoside Analogs
• Antituberculosis agents
  • Nicotinic acid derivatives
  • Rifamycin derivatives
  • Streptomyces derivatives
  • Aminosalicylates
  • Diarylquinolines
  • Hydrazide derivatives
• Antitreponemal agents
• Vaccines
  • DNA & Recombinant vector Vaccines
  • Toxoid vaccines
  • Live/attenuated Vaccines
  • Inactivated Vaccines
• Antibacterial agents
  • Clindamycin
  • Sulfonamides
  • Tetracyclines
  • Vancomycin
  • Cephalosporins
  • Carbapenems
  • Fluoroquinolones
  • Penicillins
  • Macrolides

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Emerging Markets
• 3.8 Futuristic Market Scenario

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Anti-Infective Agents Market, By Product

• 5.1 Introduction
• 5.2 Antifungal agents
  • 5.2.1 Azoles
    • 5.2.1.1 Posaconazole
    • 5.2.1.2 Clotrimazole
    • 5.2.1.3 Fluconazole
    • 5.2.1.4 Itraconazole
    • 5.2.1.5 Ketoconazole
    • 5.2.1.6 Voriconazole
  • 5.2.2 Polyenes
  • 5.2.3 Allylamines
  • 5.2.4 Macrolides derivatives
  • 5.2.5 Cresemba
  • 5.2.6 Echinocandins
• 5.3 Antiviral agents
  • 5.3.1 Non-structural protein 5A (NS5A) inhibitors
  • 5.3.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  • 5.3.3 Protease Inhibitors
  • 5.3.4 Transcriptase Inhibitors
  • 5.3.5 Neuraminidase inhibitors
  • 5.3.6 Integrase strand transfer inhibitor
  • 5.3.7 Chemokine receptor antagonist
  • 5.3.8 DNA Polymerase Inhibitors
  • 5.3.9 Nucleoside Analogs
    • 5.3.9.1 Purine Nucleosides
    • 5.3.9.2 Pyrimidine Nucleosides
• 5.4 Antituberculosis agents
  • 5.4.1 Nicotinic acid derivatives
  • 5.4.2 Rifamycin derivatives
  • 5.4.3 Streptomyces derivatives
  • 5.4.4 Aminosalicylates
  • 5.4.5 Diarylquinolines
  • 5.4.6 Hydrazide derivatives
• 5.5 Antitreponemal agents
• 5.6 Vaccines
  • 5.6.1 DNA & Recombinant vector Vaccines
  • 5.6.2 Toxoid vaccines
  • 5.6.3 Live/attenuated Vaccines
  • 5.6.4 Inactivated Vaccines
• 5.7 Antibacterial agents
  • 5.7.1 Clindamycin
    • 5.7.1.1 B-Lactam Antibiotics
    • 5.7.1.2 Oxazolidinones
    • 5.7.1.3 Aminoglycosides
    • 5.7.1.4 Quinolones
  • 5.7.2 Sulfonamides
  • 5.7.3 Tetracyclines
  • 5.7.4 Vancomycin
  • 5.7.5 Cephalosporins
  • 5.7.6 Carbapenems
  • 5.7.7 Fluoroquinolones
  • 5.7.8 Penicillins
    • 5.7.8.1 Penicillinase resistant penicillins
    • 5.7.8.2 Natural penicillins
    • 5.7.8.3 Beta-lactamase inhibitors
    • 5.7.8.4 Antipseudomonal penicillins
    • 5.7.8.5 Aminopenicillins
  • 5.7.9 Macrolides
    • 5.7.9.1 Erythromycin
    • 5.7.9.2 Sulfisoxazole
    • 5.7.9.3 Azithromycin
    • 5.7.9.4 Clarithromycin XL

6 Anti-Infective Agents Market, By Geography

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 US
  • 6.2.2 Canada
  • 6.2.3 Mexico
• 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 UK
  • 6.3.3 Italy
  • 6.3.4 France
  • 6.3.5 Spain
  • 6.3.6 Rest of Europe
• 6.4 Asia Pacific
  • 6.4.1 Japan
  • 6.4.2 China
  • 6.4.3 India
  • 6.4.4 Australia
  • 6.4.5 New Zealand
  • 6.4.6 South Korea
  • 6.4.7 Rest of Asia Pacific
• 6.5 South America
  • 6.5.1 Argentina
  • 6.5.2 Brazil
  • 6.5.3 Chile
  • 6.5.4 Rest of South America
• 6.6 Middle East & Africa
  • 6.6.1 Saudi Arabia
  • 6.6.2 UAE
  • 6.6.3 Qatar
  • 6.6.4 South Africa
  • 6.6.5 Rest of Middle East & Africa

7 Key Player Activities

• 7.1 Acquisitions & Mergers
• 7.2 Agreements, Partnerships, Collaborations and Joint Ventures
• 7.3 Product Launch & Expansions
• 7.4 Other Activities

8 Leading Companies

• 8.1 Pfizer Ltd
• 8.2 Ranbaxy Laboratories Ltd
• 8.3 Sun Pharmaceutical Industries Ltd.
• 8.4 AstraZeneca Plc
• 8.5 Boehringer Ingelheim
• 8.6 Bristol-Myers Squibb Co
• 8.7 Abbott Laboratories
• 8.8 Bayer Healthcare AG
• 8.9 Cipla Ltd
• 8.10 GlaxoSmithKline Pharmaceuticals Ltd
• 8.11 Merck & Co., Inc
• 8.12 Novartis AG
• 8.13 Glenmark Pharmaceuticals Ltd
• 8.14 Lupin Ltd
• 8.15 Panacea Biotech Ltd
• 8.16 Claris Life Sciences Ltd

List of Tables

• Table 1 Global Anti-Infective Agents Market Outlook, By Region (2014-2023) ($MN)
• Table 2 Global Anti-Infective Agents Market Outlook, By Product (2014-2023) ($MN)
• Table 3 Global Anti-Infective Agents Market Outlook, By Antifungal agents (2014-2023) ($MN)
• Table 4 Global Anti-Infective Agents Market Outlook, By Azoles (2014-2023) ($MN)
• Table 5 Global Anti-Infective Agents Market Outlook, By Polyenes (2014-2023) ($MN)
• Table 6 Global Anti-Infective Agents Market Outlook, By Allylamines (2014-2023) ($MN)
• Table 7 Global Anti-Infective Agents Market Outlook, By Macrolides derivatives (2014-2023) ($MN)
• Table 8 Global Anti-Infective Agents Market Outlook, By Cresemba (2014-2023) ($MN)
• Table 9 Global Anti-Infective Agents Market Outlook, By Echinocandins (2014-2023) ($MN)
• Table 10 Global Anti-Infective Agents Market Outlook, By Antiviral agents (2014-2023) ($MN)
• Table 11 Global Anti-Infective Agents Market Outlook, By Non-structural protein 5A (NS5A) inhibitors (2014-2023) ($MN)
• Table 12 Global Anti-Infective Agents Market Outlook, By Non-nucleoside reverse transcriptase inhibitors (NNRTIs) (2014-2023) ($MN)
• Table 13 Global Anti-Infective Agents Market Outlook, By Protease Inhibitors (2014-2023) ($MN)
• Table 14 Global Anti-Infective Agents Market Outlook, By Transcriptase Inhibitors (2014-2023) ($MN)
• Table 15 Global Anti-Infective Agents Market Outlook, By Neuraminidase inhibitors (2014-2023) ($MN)
• Table 16 Global Anti-Infective Agents Market Outlook, By Integrase strand transfer inhibitor (2014-2023) ($MN)
• Table 17 Global Anti-Infective Agents Market Outlook, By Chemokine receptor antagonist (2014-2023) ($MN)
• Table 18 Global Anti-Infective Agents Market Outlook, By DNA Polymerase Inhibitors (2014-2023) ($MN)
• Table 19 Global Anti-Infective Agents Market Outlook, By Nucleoside Analogs (2014-2023) ($MN)
• Table 20 Global Anti-Infective Agents Market Outlook, By Antituberculosis agents (2014-2023) ($MN)
• Table 21 Global Anti-Infective Agents Market Outlook, By Nicotinic acid derivatives (2014-2023) ($MN)
• Table 22 Global Anti-Infective Agents Market Outlook, By Rifamycin derivatives (2014-2023) ($MN)
• Table 23 Global Anti-Infective Agents Market Outlook, By Streptomyces derivatives (2014-2023) ($MN)
• Table 24 Global Anti-Infective Agents Market Outlook, By Aminosalicylates (2014-2023) ($MN)
• Table 25 Global Anti-Infective Agents Market Outlook, By Diarylquinolines (2014-2023) ($MN)
• Table 26 Global Anti-Infective Agents Market Outlook, By Hydrazide derivatives (2014-2023) ($MN)
• Table 27 Global Anti-Infective Agents Market Outlook, By Antitreponemal agents (2014-2023) ($MN)
• Table 28 Global Anti-Infective Agents Market Outlook, By Vaccines (2014-2023) ($MN)
• Table 29 Global Anti-Infective Agents Market Outlook, By DNA & Recombinant vector Vaccines (2014-2023) ($MN)
• Table 30 Global Anti-Infective Agents Market Outlook, By Toxoid vaccines (2014-2023) ($MN)
• Table 31 Global Anti-Infective Agents Market Outlook, By Live/attenuated Vaccines (2014-2023) ($MN)
• Table 32 Global Anti-Infective Agents Market Outlook, By Inactivated Vaccines (2014-2023) ($MN)
• Table 33 Global Anti-Infective Agents Market Outlook, By Antibacterial agents (2014-2023) ($MN)
• Table 34 Global Anti-Infective Agents Market Outlook, By Clindamycin (2014-2023) ($MN)
• Table 35 Global Anti-Infective Agents Market Outlook, By Sulfonamides (2014-2023) ($MN)
• Table 36 Global Anti-Infective Agents Market Outlook, By Tetracyclines (2014-2023) ($MN)
• Table 37 Global Anti-Infective Agents Market Outlook, By Vancomycin (2014-2023) ($MN)
• Table 38 Global Anti-Infective Agents Market Outlook, By Cephalosporins (2014-2023) ($MN)
• Table 39 Global Anti-Infective Agents Market Outlook, By Carbapenems (2014-2023) ($MN)
• Table 40 Global Anti-Infective Agents Market Outlook, By Fluoroquinolones (2014-2023) ($MN)
• Table 41 Global Anti-Infective Agents Market Outlook, By Penicillins (2014-2023) ($MN)
• Table 42 Global Anti-Infective Agents Market Outlook, By Penicillinase resistant penicillins (2014-2023) ($MN)
• Table 43 Global Anti-Infective Agents Market Outlook, By Natural penicillins (2014-2023) ($MN)
• Table 44 Global Anti-Infective Agents Market Outlook, By Beta-lactamase inhibitors (2014-2023) ($MN)
• Table 45 Global Anti-Infective Agents Market Outlook, By Antipseudomonal penicillins (2014-2023) ($MN)
• Table 46 Global Anti-Infective Agents Market Outlook, By Aminopenicillins (2014-2023) ($MN)
• Table 47 Global Anti-Infective Agents Market Outlook, By Macrolides (2014-2023) ($MN)
• Table 48 Global Anti-Infective Agents Market Outlook, By Erythromycin (2014-2023) ($MN)
• Table 49 Global Anti-Infective Agents Market Outlook, By Sulfisoxazole (2014-2023) ($MN)
• Table 50 Global Anti-Infective Agents Market Outlook, By Azithromycin (2014-2023) ($MN)
• Table 51 Global Anti-Infective Agents Market Outlook, By Clarithromycin XL (2014-2023) ($MN)

Note: North America, Europe, Asia Pacific, South America, Middle East and Africa are represented in above manner.